ArticleFrontiers in cell and developmental biology2026
A putative prognostic model for lung adenocarcinoma based on crotonylation-related genes by bioinformatics and experimental verification.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Protein crotonylation is a novel post-translational modification implicated in tumorigenesis and progression. Its putative roles and mechanisms in lung adenocarcinoma (LUAD), however, remain incompletely elucidated. Methods: We analyzed the expression of crotonylation-related genes (CRGs) in LUAD samples and identified differentially expressed genes for gene set variation analysis (GSVA). Using GSVA scores as phenotypic traits, weighted gene co-expression network analysis (WGCNA) was applied to identify key module genes. A putative prognostic model was subsequently constructed via Lasso-Cox regression. Functional enrichment, gene mutation analysis, and immune infiltration analyses were conducted to compare high- and low-risk groups. Furthermore, cellular experiments were performed to validate the putative role of the hub gene FAM83A and its regulation of key glycolytic enzymes PKM2 and LDHA. Results: We established a putative crotonylation-related prognostic model for LUAD, which effectively stratified patients into high- and low-risk groups with significantly different overall survival. Functional analysis suggested putative disparities in metabolic pathways between the two groups. Mutation landscape analysis revealed distinct genomic variation patterns, while immune infiltration assessment indicated a putative immune-evasion phenotype in high-risk patients. Cellular assays demonstrated that FAM83A enhances lung cancer cell proliferation, putatively through promoting glycolysis. Our findings establish that FAM83A integrates histone H3K27 crotonylation signaling to drive transcriptional reprogramming of glycolytic metabolism, specifically upregulating key enzymes PKM2 and LDHA. Conclusion: This study proposes a putative prognostic model based on CRGs for LUAD outcome prediction. The hub gene FAM83A may facilitate lung cancer cell growth by regulating glycolysis via PKM2 and LDHA, offering a novel theoretical foundation and a potential target for prognostic assessment and targeted therapy in LUAD patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.